Sodium zirconium cyclosilicate for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 29 Aug 2024: Trial registered, NCT06578078
  2. 3 Oct 2024: Trial started, NCT06578078

The trials

NCT04789239: OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

State
Under way
Phase
Phase 2
People
110 planned
Started
1 Sep 2021
Primary completion
31 Dec 2025
Arms
SZC + MRA treated heart failure patients
Results
None posted
  1. 9 Mar 2021: Trial registered
  2. 1 Sep 2021: Trial started

NCT06578078: A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients

State
Under way
Phase
Phase 3
People
94 planned
Started
3 Oct 2024
Primary completion
30 Dec 2026
Arms
SZC group
Results
None posted
  1. 29 Aug 2024: Trial registered
  2. 3 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Lokelma.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.